What Is Stage 3 Mesothelioma?

How Stage 3 Is Classified

Stage 3 pleural mesothelioma is divided into substages 3A and 3B, reflecting different degrees of tumor invasion and lymph node involvement. In Stage 3A, the tumor has invaded the chest wall, mediastinum, or pericardium (heart lining) on one side, with involvement of lymph nodes on the same side of the chest. Some Stage 3A patients may still be candidates for surgical resection depending on their overall health and the tumor's specific location.

In Stage 3B, the tumor has invaded more extensively — potentially into the spine, ribs, contralateral pleura, or through the diaphragm into the peritoneum. Lymph node involvement may extend to the opposite side of the chest or the supraclavicular nodes. Surgery is generally not feasible at Stage 3B, and treatment focuses on systemic therapies.

Stage 3 is one of the most common stages at the time of initial diagnosis because mesothelioma symptoms often do not become severe enough to prompt a thorough medical workup until the disease has advanced to this point.

Symptoms at Stage 3

By Stage 3, symptoms are typically significant and impact daily life. Patients commonly experience persistent and worsening chest pain, severe shortness of breath, difficulty swallowing (dysphagia), fatigue, and unintentional weight loss. Large pleural effusions are common and may require repeated drainage procedures to relieve breathing difficulty.

As the tumor invades the chest wall, patients may experience pain that is localized to specific areas and worsens with movement or deep breathing. Nerve involvement can cause referred pain to the shoulder or arm. These symptoms can be managed with appropriate palliative care, even as disease-directed treatment continues.

Treatment Options

Treatment for Stage 3 mesothelioma is individualized based on the substage, cell type, and patient's overall condition. For select Stage 3A patients with epithelioid histology and good performance status, surgery (typically pleurectomy/decortication) combined with chemotherapy may still provide benefit. However, the primary goal at this stage often shifts from cure to disease control and symptom management.

Chemotherapy remains a standard treatment, with pemetrexed and cisplatin or carboplatin as the first-line regimen. Immunotherapy — particularly the combination of nivolumab and ipilimumab — has been approved as a first-line treatment for unresectable pleural mesothelioma and has demonstrated meaningful survival benefits in clinical trials.

Palliative treatments such as pleurodesis (to prevent fluid recurrence), pain management, and respiratory support play an important role in maintaining quality of life. Clinical trials may also provide access to promising new therapies that are not yet widely available.

Prognosis

Median survival for Stage 3 mesothelioma is approximately 12 to 18 months with treatment, though some patients — particularly those with epithelioid cell type who respond well to immunotherapy — may significantly exceed this estimate. Prognosis is highly individual and depends on multiple factors beyond staging alone.

The emergence of immunotherapy has been particularly meaningful for patients diagnosed at later stages, offering a treatment option that was not available just a few years ago. Patients should discuss all available options, including clinical trials, with their oncology team.

Legal Urgency at Stage 3

A Stage 3 diagnosis often introduces a sense of urgency in pursuing legal compensation. Because the disease is more advanced, courts may grant expedited discovery or trial schedules. Preserving testimony through early depositions ensures that the patient's account of their asbestos exposure is documented regardless of what the future holds. An experienced mesothelioma attorney can guide families through this process while the patient focuses on treatment.